Thrombosis in primary myelofibrosis: Incidence and risk factors

Tiziano Barbui, Alessandra Carobbio, Francisco Cervantes, Alessandro M. Vannucchi, Paola Guglielmelli, Elisabetta Antonioli, Alberto Alvarez-Larrán, Alessandro Rambaldi, Guido Finazzi, Giovanni Barosi

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

We assessed frequency and predictive factors for major cardiovascular (CV) events in 707 patients with primary myelo-fibrosis (PMF) followed in 4 European institutions. A total of 236 deaths (33%) were recorded for an overall mortality of 7.7% patient-years (pt-yr). Fatal and nonfatal thromboses were registered in 51 (7.2%) patients, with a rate of 1.75% pt-yr. If deaths from non-CV causes were considered as competing events, we estimated that the adjusted rate of major thrombotic events would have been 2.2% pt-yr. In a multivariable model, age older than 60 years (hazard ratio [HR], 2.34; 95% confidence interval [CI], 1.24-4.39, P = .01) and JAK2 mutational status (HR, 1.92; 95% CI, 1.10-3.34; P = .02) were significantly associated with thrombosis, whereas the strength of the association between leukocyte count higher than 15 x 109/L and CV events was of borderline significance (HR, 1.72; 95% CI, 0.97-2.72; P = .06). The highest incidence of fatal and nonfatal thrombosis was observed when the mutation was present along with leukocytosis (3.9% pt-yr; HR, 3.13; 95% CI, 1.26-7.81). This study is the largest hitherto carried out in this setting and shows that the rate of major CV events in PMF is comparable with that reported in essential thrombocythemia, and it is increased in aged patients and those with JAK2 V617F mutation and leukocytosis.

Original languageEnglish
Pages (from-to)778-782
Number of pages5
JournalBlood
Volume115
Issue number4
DOIs
Publication statusPublished - Jan 28 2010

Fingerprint

Primary Myelofibrosis
Hazards
Thrombosis
Incidence
Confidence Intervals
Leukocytosis
Fibrosis
Essential Thrombocythemia
Mutation
Leukocyte Count
Mortality

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Barbui, T., Carobbio, A., Cervantes, F., Vannucchi, A. M., Guglielmelli, P., Antonioli, E., ... Barosi, G. (2010). Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood, 115(4), 778-782. https://doi.org/10.1182/blood-2009-08-238956

Thrombosis in primary myelofibrosis : Incidence and risk factors. / Barbui, Tiziano; Carobbio, Alessandra; Cervantes, Francisco; Vannucchi, Alessandro M.; Guglielmelli, Paola; Antonioli, Elisabetta; Alvarez-Larrán, Alberto; Rambaldi, Alessandro; Finazzi, Guido; Barosi, Giovanni.

In: Blood, Vol. 115, No. 4, 28.01.2010, p. 778-782.

Research output: Contribution to journalArticle

Barbui, T, Carobbio, A, Cervantes, F, Vannucchi, AM, Guglielmelli, P, Antonioli, E, Alvarez-Larrán, A, Rambaldi, A, Finazzi, G & Barosi, G 2010, 'Thrombosis in primary myelofibrosis: Incidence and risk factors', Blood, vol. 115, no. 4, pp. 778-782. https://doi.org/10.1182/blood-2009-08-238956
Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al. Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood. 2010 Jan 28;115(4):778-782. https://doi.org/10.1182/blood-2009-08-238956
Barbui, Tiziano ; Carobbio, Alessandra ; Cervantes, Francisco ; Vannucchi, Alessandro M. ; Guglielmelli, Paola ; Antonioli, Elisabetta ; Alvarez-Larrán, Alberto ; Rambaldi, Alessandro ; Finazzi, Guido ; Barosi, Giovanni. / Thrombosis in primary myelofibrosis : Incidence and risk factors. In: Blood. 2010 ; Vol. 115, No. 4. pp. 778-782.
@article{ae8686d9011c4631b1d6369604d4fcf7,
title = "Thrombosis in primary myelofibrosis: Incidence and risk factors",
abstract = "We assessed frequency and predictive factors for major cardiovascular (CV) events in 707 patients with primary myelo-fibrosis (PMF) followed in 4 European institutions. A total of 236 deaths (33{\%}) were recorded for an overall mortality of 7.7{\%} patient-years (pt-yr). Fatal and nonfatal thromboses were registered in 51 (7.2{\%}) patients, with a rate of 1.75{\%} pt-yr. If deaths from non-CV causes were considered as competing events, we estimated that the adjusted rate of major thrombotic events would have been 2.2{\%} pt-yr. In a multivariable model, age older than 60 years (hazard ratio [HR], 2.34; 95{\%} confidence interval [CI], 1.24-4.39, P = .01) and JAK2 mutational status (HR, 1.92; 95{\%} CI, 1.10-3.34; P = .02) were significantly associated with thrombosis, whereas the strength of the association between leukocyte count higher than 15 x 109/L and CV events was of borderline significance (HR, 1.72; 95{\%} CI, 0.97-2.72; P = .06). The highest incidence of fatal and nonfatal thrombosis was observed when the mutation was present along with leukocytosis (3.9{\%} pt-yr; HR, 3.13; 95{\%} CI, 1.26-7.81). This study is the largest hitherto carried out in this setting and shows that the rate of major CV events in PMF is comparable with that reported in essential thrombocythemia, and it is increased in aged patients and those with JAK2 V617F mutation and leukocytosis.",
author = "Tiziano Barbui and Alessandra Carobbio and Francisco Cervantes and Vannucchi, {Alessandro M.} and Paola Guglielmelli and Elisabetta Antonioli and Alberto Alvarez-Larr{\'a}n and Alessandro Rambaldi and Guido Finazzi and Giovanni Barosi",
year = "2010",
month = "1",
day = "28",
doi = "10.1182/blood-2009-08-238956",
language = "English",
volume = "115",
pages = "778--782",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Thrombosis in primary myelofibrosis

T2 - Incidence and risk factors

AU - Barbui, Tiziano

AU - Carobbio, Alessandra

AU - Cervantes, Francisco

AU - Vannucchi, Alessandro M.

AU - Guglielmelli, Paola

AU - Antonioli, Elisabetta

AU - Alvarez-Larrán, Alberto

AU - Rambaldi, Alessandro

AU - Finazzi, Guido

AU - Barosi, Giovanni

PY - 2010/1/28

Y1 - 2010/1/28

N2 - We assessed frequency and predictive factors for major cardiovascular (CV) events in 707 patients with primary myelo-fibrosis (PMF) followed in 4 European institutions. A total of 236 deaths (33%) were recorded for an overall mortality of 7.7% patient-years (pt-yr). Fatal and nonfatal thromboses were registered in 51 (7.2%) patients, with a rate of 1.75% pt-yr. If deaths from non-CV causes were considered as competing events, we estimated that the adjusted rate of major thrombotic events would have been 2.2% pt-yr. In a multivariable model, age older than 60 years (hazard ratio [HR], 2.34; 95% confidence interval [CI], 1.24-4.39, P = .01) and JAK2 mutational status (HR, 1.92; 95% CI, 1.10-3.34; P = .02) were significantly associated with thrombosis, whereas the strength of the association between leukocyte count higher than 15 x 109/L and CV events was of borderline significance (HR, 1.72; 95% CI, 0.97-2.72; P = .06). The highest incidence of fatal and nonfatal thrombosis was observed when the mutation was present along with leukocytosis (3.9% pt-yr; HR, 3.13; 95% CI, 1.26-7.81). This study is the largest hitherto carried out in this setting and shows that the rate of major CV events in PMF is comparable with that reported in essential thrombocythemia, and it is increased in aged patients and those with JAK2 V617F mutation and leukocytosis.

AB - We assessed frequency and predictive factors for major cardiovascular (CV) events in 707 patients with primary myelo-fibrosis (PMF) followed in 4 European institutions. A total of 236 deaths (33%) were recorded for an overall mortality of 7.7% patient-years (pt-yr). Fatal and nonfatal thromboses were registered in 51 (7.2%) patients, with a rate of 1.75% pt-yr. If deaths from non-CV causes were considered as competing events, we estimated that the adjusted rate of major thrombotic events would have been 2.2% pt-yr. In a multivariable model, age older than 60 years (hazard ratio [HR], 2.34; 95% confidence interval [CI], 1.24-4.39, P = .01) and JAK2 mutational status (HR, 1.92; 95% CI, 1.10-3.34; P = .02) were significantly associated with thrombosis, whereas the strength of the association between leukocyte count higher than 15 x 109/L and CV events was of borderline significance (HR, 1.72; 95% CI, 0.97-2.72; P = .06). The highest incidence of fatal and nonfatal thrombosis was observed when the mutation was present along with leukocytosis (3.9% pt-yr; HR, 3.13; 95% CI, 1.26-7.81). This study is the largest hitherto carried out in this setting and shows that the rate of major CV events in PMF is comparable with that reported in essential thrombocythemia, and it is increased in aged patients and those with JAK2 V617F mutation and leukocytosis.

UR - http://www.scopus.com/inward/record.url?scp=77949328094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949328094&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-08-238956

DO - 10.1182/blood-2009-08-238956

M3 - Article

C2 - 19965680

AN - SCOPUS:77949328094

VL - 115

SP - 778

EP - 782

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -